Aachen, Germany (ots/PRNewswire) - Grünenthal announced today that
Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and
Member of the Corporate Executive Board effective 1 January 2020.
Since July 2019, Jan has already served as acting CSO, leading the
strategic re-alignment of Grünenthal's R&D organisation.
Jan brings over 15 years of experience in healthcare and the
biopharmaceutical industry. He joined Grünenthal in July 2017 as Head
Corporate Strategy and Portfolio Management, working at the interface
between strategy, research, development and commercial. Prior to
joining Grünenthal, he served as a member of the global R&D
Leadership Team at Takeda in Boston, where he held the position of
Head Strategic Management & Planning. Previously, Jan was a leader in
McKinsey & Company's global Pharmaceutical and Medical Products
practice working with clients in Europe, US and Asia. He started his
career as a resident in cardiology and a project leader in Clinical
Development and Medical Affairs at Novartis. Jan is a Medical Doctor
by training, married and has two children.
"I'm very happy to continue working with Jan as CSO. He has
accompanied us through our transformation process and led the
development and implementation of our new R&D strategy and operating
model, which puts us in an even stronger position to deliver
meaningful innovation to patients and live up to our vision of a
world free of pain," Gabriel Baertschi, Grünenthal CEO, said. "I'm
glad to welcome Jan as a new member of the Corporate Executive Board.
I firmly believe that his appointment will give Grünenthal's new R&D
organisation continuity after a major transformation and sets us up
for success to fully execute on our strategy," Wilhelm Moll, Chairman
of the Supervisory Board, added.
"I am very much looking forward to continuing my work at Grünenthal
as Chief Scientific Officer and to further building our pipeline of
highly innovative assets addressing the high unmet medical needs in
the area of pain," Jan Adams, Grünenthal CSO, said. "Research and
Development is at the core of our strategy and we drive promising
assets with a wide range of therapeutic modalities and a strong
network around the globe."
Grünenthal is a global leader in pain management and related
diseases. As a science-based, privately-owned pharmaceutical company,
we have a long track record of bringing innovative treatments and
state-of-the-art technologies to patients worldwide. Our purpose is
to change lives for the better - and innovation is our passion. We
are focussing all of our activities and efforts on working towards
our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in
30 countries across Europe, Latin America and the US. Our products
are available in more than 100 countries. In 2018, Grünenthal
employed around 4,900 people and achieved sales of EUR 1.3 bn.
Follow us on:
LinkedIn: Grunenthal Group
For further information please contact:St?pán Krá?ala, Head Global
Phone: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany
Digital press kit: http://www.ots.at/pressemappe/PR118252/aom
Aktien auf dem Radar: DO&CO , Marinomed Biotech , EVN , Zumtobel , Addiko Bank , Amag , Rosenbauer , Uniqa , Palfinger , Mayr-Melnhof , voestalpine , RBI , Pierer Mobility AG , FACC , Semperit , SW Umwelttechnik , UBM , Frauenthal , Oberbank AG Stamm , UIAG , Warimpex , BKS Bank Stamm .
Die Uniqa Group ist eine führende Versicherungsgruppe, die in Österreich und Zentral- und Osteuropa tätig ist. Die Gruppe ist mit ihren mehr als 20.000 Mitarbeitern und rund 40 Gesellschaften in 18 Ländern vor Ort und hat mehr als 10 Millionen Kunden.
>> Besuchen Sie 54 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER